Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Turoctocog alfa prevented, treated bleeds in previously untreated pediatric patients with severe hemophilia A

Key clinical point: The recombinant factor VIII turoctocog alfa effectively prevented and stopped bleeds in previously untreated children with hemophilia A.

Major finding: Of 58 prophylactically treated patients, 25 (43.1%) developed factor VIII inhibitors in the first 50 exposure days.

Study details: Results of guardian 4, a multinational, nonrandomized, phase 3 clinical trial including 60 pediatric patients with hemophilia A.

Disclosures: Novo Nordisk sponsored the guardian 4 study. The lead author reported disclosures related to Novo Nordisk, Shire, Bayer, and Octapharma.


Yaish HM et al. Haemophilia. 2019 Dec 9. doi: 10.1111/hae.13883.